Cadrenal Therapeutics, Inc. — Form 8-K
Filed July 17, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 45/100
What the filing says
James J. Ferguson III, Chief Medical Officer of Cadrenal Therapeutics, voluntarily resigned effective July 31, 2026 (dated July 9, 2026). In exchange for a broad release of all employment-related claims, the company will pay 100% of his COBRA health insurance premiums for 6 months post-separation, plus accrued final wages and business expenses. No severance payment amount is disclosed in the filing.
Why this rating
CMO departure is operationally notable for a $24.9M biotech but not quantified as material; no severance figure disclosed. COBRA cost (~$3–8K likely) is immaterial to company scale.
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.